Eisai Innovation, Inc.
Corporate VCSan Francisco · 5 people tracked
Investment thesis
Eisai Innovation seeks to identify and invest in innovative biotech and digital health companies that create synergies with Eisai's scientific capabilities and network. The investment strategy focuses on cutting-edge drug modalities, digital healthcare solutions, and emerging technologies in therapeutic areas with high unmet medical needs, particularly oncology and neurology. Through venture investment and M&A, the firm aims to accelerate Eisai's transformation into a top-10 global healthcare company while fostering innovation and translating emerging research into patient-centric solutions.
Source: firm website, verified Aug 7, 2026.
Team · 5 people
from the firm's website & public directoriesWhat they invest in
from 27 of 30 portfolio companiesBiotech ×21Healthtech ×17Deep Tech ×12Digital Health ×7AI & Machine Learning ×6Medical Devices ×6Wellness & Fitness ×2Enterprise Software ×1
HQs:United States×6Japan×3
Investments · 30 tracked
founders shown can be your intro pathBy year:2025 · 22024 · 13 dated
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)inLAURA TADVALKAR(Director)
Co-investorsDroia VenturesNovartis Venture FundRA Capital
Sift Biosciences develops T-cell immunotherapies for cancer and autoimmune diseases, using an AI-driven discovery platform combined with metagenomics and high-throughput cellular screening to identify microbially derived molecules that activate memory T cells.
AI & Machine LearningBiotechHealthtechSan Carlos, US
Yue Clare Lou(Co-Founder & CEO)inYue Lou(Executive Officer, Director)
BoardKevin Barrett(Director)Altar Munis(Director)
Co-investorsSBI HoldingsFifty YearsFREEFLOW
PRISM BioLab is a biotechnology company that develops PepMetics, a proprietary drug discovery platform of small molecules designed to mimic α-helix or β-turn peptides, aiming to target proteins previously considered "undruggable." The company maintains a screening library of over 20,000 compounds and partners with pharmaceutical firms on drug discovery programs.
AI & Machine LearningBiotechDeep TechTokyo, JP
Co-investorsDBJ CapitalNewton Biocapital
Altoida operates a digital NeuroMarker Platform that uses neuroscience-driven tasks, machine learning, augmented reality, and sensor data (motion, speech, touch) to detect early cognitive decline.
AI & Machine LearningDigital HealthMedical Devices
Co-investorsAlpana VenturesHikma VenturesWhitecap Venture PartnersM VenturesVI Partners
Japanese company providing personal health record (PHR) services that use individual health data to deliver personalized health advice, including apps such as "パシャっとカルテ" and dietary support tools.
Digital HealthHealthtechWellness & Fitness
Beren Therapeutics is a public benefit biotechnology corporation developing cyclodextrin-based therapeutics for conditions involving impaired cholesterol trafficking, including Niemann-Pick disease type C (NPC) and other neurodegenerative diseases.
BiotechHealthtechMedical Devices
Jason Camm(Founder, President & Chief Executive Officer)Aaron Ondrey(Chief Financial Officer)Alex Gold(Chief Medical Officer)Jennifer Spinella(Chief Regulatory Officer & Head of Quality)Irene von Hennigs(SVP, Global Medical Affairs)Bennett Smith(SVP, Commercial)
Co-investorsAlpha Wave GlobalNarya CapitalOctave Ventures LlcUTokyo Innovation Platform Co. Ltd.
BlissBio is a clinical-stage biotech company focused on discovering, developing, and commercializing oncology biological therapeutics, with multiple tumor-targeting antibody-drug conjugates (ADCs) in Phase I and Phase II clinical trials.
Biotech
Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases.
BiotechHealthtech
Co-investorsMRL Ventures FundSV Health Investors
Casma Therapeutics develops therapies based on targeted autophagy, using its PHLYT (Phagosome-Lysosome Targeting) platform to initiate target-specific degradation of disease-causing cellular components regardless of size or complexity.
BiotechDeep Tech
Co-investorsAstellas Venture Management LLCOno Venture Investment, Inc.
Cogstate provides cognitive assessment tools and scientific support services for clinical trials and drug development programs, serving pharmaceutical companies, biotech firms, and academic research collaboratives.
BiotechDigital HealthHealthtech
Darmiyan develops medical AI and brain imaging software for early detection and monitoring of neurodegenerative diseases, particularly Alzheimer's.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Padideh Kamali-Zare(Founder)inKaveh Vejdani(Founder/Chief Medical and Technology Officer)in
BoardShirai Takehiro(Director)
Co-investorsAAF Management Ltd.Y CombinatorThrive Capital
eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
BiotechDeep TechMedical Devices
Mike Curtis, Ph.D.(President & Chief Executive Officer)
Co-investorsAlta PartnersAltium CapitalFresenius Medical Care VenturesKhosla VenturesLux Capital
Eisai is a pharmaceutical company focused on drug discovery, research and development, and clinical research, with a stated emphasis on serving patients and their families.
BiotechHealthtech
Iambic is a clinical-stage life science and technology company that develops novel medicines using an AI-driven drug discovery and development platform.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Co-Founder & CEO)Fred Manby(Co-Founder & CTO)Neil Josephson(Chief Medical Officer)Pete Olson(Chief Scientific Officer)Michael Secora(Chief Financial Officer and Chief Corporate Development Officer)
Co-investorsAbingworthAscenta CapitalCatalio Capital ManagementAlumni VenturesCatalio Capital Management, LPFREEFLOW+2 more
Neuroglee provides memory and dementia care programs, including support for care partners, delivered through value-based arrangements.
Digital HealthHealthtechLongevity
Aniket Singh Rajput(Founder)in
Co-investorsOpenspace Ventures
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety.
BiotechDeep Tech
Ophidion is an early-stage CNS biopharmaceutical company developing a non-invasive carrier technology that delivers gene-silencing agents and other therapeutics across the blood-brain barrier into the brain.
BiotechDeep TechHealthtechBethlehem, US
Julie Miwa(Director, Promoter)inYacoub Habib(Executive Officer, Director, Promoter)
BoardMichael Lark(Director)Scott Fishman(Director)Claudine Bruck(Director)
Co-investorsRobin Hood Ventures
Oura Ring is a wearable smart ring that collects and analyzes 50+ personal health metrics to provide insights on sleep, fitness, and wellness for individual users.
HardwareHealthtechWellness & Fitness
Tom Hale(CEO)in
Co-investorsA-Rod CorpAble PartnersAlumni VenturesBasecamp FundBold Capital PartnersBOLD Longevity+21 more
Periotherapia is a drug discovery company developing new treatments for intractable diseases, including neutralizing antibodies targeting periostin.
BiotechDeep TechHealthtech
ProTgen is a clinical-stage biotechnology company developing targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence.
BiotechHealthtechToronto
Juan Carlos Zuniga-Pflucker(Executive Officer, Director)
BoardFei Shen(Director)Ferdinand Massari(Director)
Co-investorsFACIT (Fight Against Cancer Innovation Trust)
SEED Therapeutics develops de novo molecular glue degraders for targeted protein degradation, using its RITE3 platform to match E3 ligases with disease-causing target proteins.
BiotechDeep TechHealthtech
Lan Huang(Ph.D.)
SOLA Biosciences develops gene therapies for conformational diseases, using its JUMP70 platform to activate the body's protein-folding machinery to refold or remove misfolded proteins.
BiotechDeep Tech
Co-investorsMC Healthcare VenturesUTEC
Tacit develops RNA repair technology called Splicing-Directed Repair, which uses naturally-occurring biological systems to fix genetic mutations as an alternative to conventional gene editing.
BiotechDeep TechHealthtech
Co-investorsMitsui Global InvestmentKdT Ventures
Unlearn develops AI-powered digital twins and data analytics tools to optimize clinical trial design and execution for pharmaceutical companies.
AI & Machine LearningBiotechDeep TechEnterprise SoftwareSan Francisco, US
Charles Fisher(Founder & CEO)inAaron Smith(Founder)
Co-investors8VCAlumni VenturesBasecamp FundDCVC (Data Collective)Flucas VenturesInsight Partners+4 more
Co-investorsOrbiMed
Voluntis provides a regulated digital health platform for pharmaceutical and medtech companies to build and manage patient-facing solutions across the patient journey, including symptom management, adherence and dosage support.
Digital HealthHealthtechSaaS
Co-investorsKaristaSanofi VenturesVesalius Biocapital Partners
Allm develops medical ICT products and digital solutions that connect patients, healthcare providers, and nursing care services.
Digital HealthHealthtechMedical Devices
Co-investorsAsia Africa Investment & Consulting (AAIC)Fast Track Initiative
Exits · 1
IPOs and acquisitions across the tracked portfolioCarawayacq. by Merck
Portfolio news
latest coverage across their companiesOura · pulse2.com · Jul 17, 2026

Iambic · geekwire.com · Jul 13, 2026
Neuroglee Health · trysignalbase.com · Mar 25, 2025
Frequently asked questions
- How many investments has Eisai Innovation, Inc. made?
- Eisai Innovation, Inc. has 30 tracked investments, 1 of which have exited via acquisition or IPO, including 3 dated in the last 24 months.
- What sectors does Eisai Innovation, Inc. focus on?
- Eisai Innovation, Inc. focuses on Biotech, Digital Health, Healthtech.
- Where is Eisai Innovation, Inc. located?
- Eisai Innovation, Inc. is headquartered in San Francisco, JP.
- Who does Eisai Innovation, Inc. co-invest with?
- Eisai Innovation, Inc. most often shares deals with Alumni Ventures, Basecamp Fund, FREEFLOW, among 72 tracked co-investors.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.







.jpeg)

